Which of the following is a common adverse effect to counsel patients starting statin therapy?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

Which of the following is a common adverse effect to counsel patients starting statin therapy?

The main concept here is recognizing the most common adverse effect patients are counseled about when starting a statin. Muscle-related symptoms are the typical reason patients notice something and seek guidance, so this is what clinicians focus on when discussing what to watch for early in therapy. Statins commonly cause muscle symptoms, collectively called statin-associated muscle symptoms. This can present as myalgias—aching or tender muscles—often with or without weakness. These symptoms can occur at any dose but are more likely when starting treatment or after increasing the dose. While most cases are mild, more significant muscle injury can occur, reflected by elevated CK levels and, in rare situations, rhabdomyolysis (characterized by severe weakness, dark urine, and potential kidney injury). That is why patients are advised to report new or worsening muscle pain, tenderness, or weakness, especially if accompanied by malaise or dark urine, so the clinician can reassess the statin therapy, check CK if indicated, and adjust the plan if needed. Nausea and vomiting can occur occasionally but are not the hallmark adverse effect of statins. Hair loss is not a typical statin-related issue, and weight gain is not commonly associated with statin therapy. Keeping the focus on muscle symptoms helps patients understand what to monitor and when to seek care.

The main concept here is recognizing the most common adverse effect patients are counseled about when starting a statin. Muscle-related symptoms are the typical reason patients notice something and seek guidance, so this is what clinicians focus on when discussing what to watch for early in therapy.

Statins commonly cause muscle symptoms, collectively called statin-associated muscle symptoms. This can present as myalgias—aching or tender muscles—often with or without weakness. These symptoms can occur at any dose but are more likely when starting treatment or after increasing the dose. While most cases are mild, more significant muscle injury can occur, reflected by elevated CK levels and, in rare situations, rhabdomyolysis (characterized by severe weakness, dark urine, and potential kidney injury). That is why patients are advised to report new or worsening muscle pain, tenderness, or weakness, especially if accompanied by malaise or dark urine, so the clinician can reassess the statin therapy, check CK if indicated, and adjust the plan if needed.

Nausea and vomiting can occur occasionally but are not the hallmark adverse effect of statins. Hair loss is not a typical statin-related issue, and weight gain is not commonly associated with statin therapy. Keeping the focus on muscle symptoms helps patients understand what to monitor and when to seek care.

More practice questions